Compare FRST & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRST | CMPX |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.3M | 408.8M |
| IPO Year | 2006 | 2020 |
| Metric | FRST | CMPX |
|---|---|---|
| Price | $16.29 | $2.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 158.2K | ★ 3.2M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | ★ 477.27 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.63 | $934.41 |
| P/E Ratio | $24.31 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.55 | $1.61 |
| 52 Week High | $16.88 | $6.88 |
| Indicator | FRST | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 53.07 | 66.20 |
| Support Level | $15.21 | $1.68 |
| Resistance Level | $16.39 | $2.47 |
| Average True Range (ATR) | 0.29 | 0.14 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 51.05 | 91.67 |
Primis Financial Corp is the bank holding company for Primis Bank, providing financial services to individuals and small and medium-sized businesses. Primis Bank offers a wide range of commercial banking services, It focuses on making loans secured mainly by commercial real estate and other types of secured and unsecured commercial loans to small and medium-sized businesses in several industries, as well as loans to individuals for a variety of purposes. The company has two reportable segments: Primis Bank. This segment specializes in providing financing services to businesses in various industries along with consumer and residential loans to individuals. Primis Mortgage. This segment specializes in originating mortgages in a majority of the U.S. The revenue is from Primis Bank.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.